Get started
Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CTXR chart


Full chart

CTXR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪74.37 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.2443 USD
Net income (FY)
‪−32.54 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪168.40 M‬
Beta (1Y)
−0.24

Employees


Employees (FY)
22
Change (1Y)
+1 +4.76%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.48 M‬ USD

About Citius Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Leonard L. Mazur
Website
citiuspharma.com
Headquarters
Cranford
Founded
2007
FIGI
BBG001QQH2N3
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CTXR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CTXR is 0.4115 USD — it has increased by 7.67% in the past 24 hours. Watch Citius Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Citius Pharmaceuticals, Inc. stocks are traded under the ticker CTXR.
CTXR stock has risen by 10.62% compared to the previous week, the month change is a 5.22% rise, over the last year Citius Pharmaceuticals, Inc. has showed a −45.86% decrease.
We've gathered analysts' opinions on Citius Pharmaceuticals, Inc. future price: according to them, CTXR price has a max estimate of 6.00 USD and a min estimate of 4.00 USD. Watch CTXR chart and read a more detailed Citius Pharmaceuticals, Inc. stock forecast: see what analysts think of Citius Pharmaceuticals, Inc. and suggest that you do with its stocks.
CTXR reached its all-time high on Feb 9, 2016 with the price of 37.4813 USD, and its all-time low was 0.3300 USD and was reached on Oct 24, 2024. View more price dynamics on CTXR chart.
See other stocks reaching their highest and lowest prices.
CTXR stock is 14.89% volatile and has beta coefficient of −0.24. Track Citius Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Citius Pharmaceuticals, Inc. there?
Today Citius Pharmaceuticals, Inc. has the market capitalization of ‪74.37 M‬, it has increased by 16.97% over the last week.
Yes, you can track Citius Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Citius Pharmaceuticals, Inc. is going to release the next earnings report on Nov 27, 2024. Keep track of upcoming events with our Earnings Calendar.
CTXR earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.05 USD resulting in a −20.00% surprise. The estimated earnings for the next quarter are −0.05 USD per share. See more details about Citius Pharmaceuticals, Inc. earnings.
Citius Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CTXR net income for the last quarter is ‪−10.57 M‬ USD, while the quarter before that showed ‪−8.54 M‬ USD of net income which accounts for −23.75% change. Track more Citius Pharmaceuticals, Inc. financial stats to get the full picture.
No, CTXR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 22.00 employees. See our rating of the largest employees — is Citius Pharmaceuticals, Inc. on this list?
Like other stocks, CTXR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Citius Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Citius Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Citius Pharmaceuticals, Inc. stock shows the sell signal. See more of Citius Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.